Clinical Trial: NCT04205552
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | University Hospital, Essen |
| Information Provided By: | University Hospital, Essen |
| Last Update Posted: | 2026-06-11 |
Study Overview
Brief Summary
The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.
Official Title
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological Response
Conditions
NSCLC Stage II, NSCLC, Stage IIIA, NSCLC, Stage I
Intervention / Treatment
- Drug: Nivolumab 10 MG/ML Intravenous Solution
- Drug: Relatlimab 10 MG/ML Intravenous Solution
Other Study ID Numbers
- CA224-063
Start Date (Actual)
2020-03-04
Primary Completion Date (Actual)
2025-11-27
Study Completion Date (Actual)
2025-11-27
Enrollment (Actual)
90
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | University Hospital, Essen |
| Information Provided By: | University Hospital, Essen |
| Last Update Posted: | 2026-06-11 |
Study Overview
Brief Summary
The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.
Official Title
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological Response
Conditions
NSCLC Stage II, NSCLC, Stage IIIA, NSCLC, Stage I
Intervention / Treatment
- Drug: Nivolumab 10 MG/ML Intravenous Solution
- Drug: Relatlimab 10 MG/ML Intravenous Solution
Other Study ID Numbers
- CA224-063
Start Date (Actual)
2020-03-04
Primary Completion Date (Actual)
2025-11-27
Study Completion Date (Actual)
2025-11-27
Enrollment (Actual)
90
Study Type
Interventional
Phase
Phase 2